Gastrointestinal complications of diabetes

American Family Physician

Volumn 77, Issue 12, 2008, Pages

  Shakil, Amer ^a   Church, Robert J ^a   Rao, Shobha S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA INTERFERON; ALPHA2A INTERFERON; AMOXICILLIN PLUS CLAVULANIC ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETHANECHOL; BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROPAMIDE; DIPHENHYDRAMINE; ERYTHROMYCIN; GEMFIBROZIL; GLIBENCLAMIDE; GLIPIZIDE; INSULIN; LACTULOSE; LAXATIVE; LEVODOPA; METFORMIN; METOCLOPRAMIDE; ONDANSETRON; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PROMETHAZINE; SORBITOL; SUCRALFATE; TEGASEROD; TOLBUTAMIDE; TROGLITAZONE; UNINDEXED DRUG; ANTIEMETIC AGENT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ALCOHOL CONSUMPTION; AMINOTRANSFERASE BLOOD LEVEL; BLADDER SPASM; BLOATING; BLURRED VISION; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DIETARY FIBER; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DROWSINESS; DRUG COST; DRUG MECHANISM; DYSTONIA; ELECTROSTIMULATION THERAPY; ENTEROPATHY; EXTRAPYRAMIDAL SYMPTOM; FECES INCONTINENCE; FOOD INTAKE; GASTRIC DYSMOTILITY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT SCINTISCANNING; GLUCOSE BLOOD LEVEL; HEMOCHROMATOSIS; HEPATITIS; HEPATITIS C; HUMAN; HYPERPROLACTINEMIA; INFECTION; IRRITABILITY; LIPID DIET; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER TOXICITY; NAUSEA; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW; SALIVATION; SATIETY; SIDE EFFECT; SMOKING; STOMACH EMPTYING; STOMACH EROSION; STOMACH MOTILITY; STOMACH OBSTRUCTION; STOMACH PARESIS; STOMACH SCINTISCANNING; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT REDUCTION; ALGORITHM; CLASSIFICATION; DRUG EFFECT; FATTY LIVER; PHYSIOLOGY;

ALGORITHMS; ANTIEMETICS; DIABETES COMPLICATIONS; FATTY LIVER; GASTRIC EMPTYING; GASTROPARESIS; HUMANS; METOCLOPRAMIDE;

EID: 47749132310     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986. (Pubitemid 23307905)
2. Bytzer P, Talley NJ, Leemon M, et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med. 2001;161(16):1989-1996. (Pubitemid 32816562)
3. Bytzer P, Talley NJ, Hammer J, Young LJ, Jones MP, Horowitz M. GI symptoms in diabetes mellitus are associated with both poor glycemic control and diabetic complications. Am J Gastroenterol. 2002;97(3):604-611. (Pubitemid 34245887)
4. Rayner CK, et al.Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care. 2001;24(2):371-381. (Pubitemid 32119141)
5. Ebert EC. Gastrointestinal complications of diabetes mellitus. Dis Mon. 2005;51(12):620-663. (Pubitemid 43183740)
6. Lluch I, Ascaso JF, Mora F, et al. Gastroesophageal reflux in diabetes mellitus. Am J Gastroenterol. 1999;94(4):919-924. (Pubitemid 29173602)
7. Camilleri M. Clinical practice. Diabetic gastroparesis [published correction appears in N Engl J Med. 2007;357(4):427]. N Engl J Med. 2007; 356(8):820-829.
8. Yoshida MM, Schuffler MD, Sumi SM. There are no morphologic abnormalities of the gastric wall or abdominal vagus in patients with diabetic gastroparesis. Gastroenterology. 1988;94(4):907-914. (Pubitemid 18103421)
9. ordög T, Takayama I, Cheung WK, Ward SM, Sanders KM. Remodeling of networks of interstitial cells of Cajal in a murine model of diabetic gastroparesis. Diabetes. 2000;49(10):1731-1739.
10. Parkman HP, Hasler WL, Fisher RS, et al. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127(5):1592-1622. (Pubitemid 39457783)
11. Tougas G, Chen Y, Coates G, et al. Standardization of a simplified scintigraphic methodology for the assessment of gastric emptying in a multicenter setting. Am J Gastroenterol. 2000;95(1):78-86. (Pubitemid 30041539)
12. Quigley EM, Hasler W, Parkman HP. AGA technical review on nausea and vomiting. Gastroenterology. 2001;120(1):263-286. (Pubitemid 32061891)
13. Abell TL, Bernstein RK, Cutts T, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil. 2006;18(4):263-283.
14. Jebbink RJ, Samsom M, Bruijs PP, et al. Hyperglycemia induces abnormalities of gastric myoelectrical activity in patients with type 1 diabetes mellitus. Gastroenterology. 1994;107(5):1390-1397. (Pubitemid 24328276)
15. Bujanda L. The effects of alcohol consumption upon the gastrointestinal tract. Am J Gastroenterol. 2000;95(12):3374-3382.
16. Galligan JJ, Vanner S. Basic and clinical pharmacology of new motility promoting agents. Neurogastroenterol Motil. 2005;17(5):643-653.
17. Degen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther. 2001;15(11):1745-1751. (Pubitemid 33001138)
18. Anand C, Al-Juburi A, Familoni B, et al. Gastric electrical stimulation is safe and effective: a long-term study in patients with drug-refractory gastroparesis in three regional centers. Digestion. 2007;75(2-3):83-89. (Pubitemid 47343953)
19. Jones MP, Maganti K. A systematic review of surgical therapy for gastroparesis. Am J Gastroenterol. 2003;98(10):2122-2129. (Pubitemid 37305346)
20. Maganti K, et al. oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol. 2003;98(2):259-263. (Pubitemid 36232369)
21. Virally-Monod M, Tielmans D, Kevorkian JP, et al. Chronic diarrhoea and diabetes mellitus: prevalence of small intestinal bacterial overgrowth. Diabetes Metab. 1998;24(6):530-536. (Pubitemid 29048422)
22. Maleki D, et al. Pilot study of pathophysiology of constipation among community diabetics. Dig Dis Sci. 1998;43(11):2373-2378. (Pubitemid 28531306)
23. Angulo P, et al. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346(16):1221-1231.
24. American Gastroenterological Association. American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology. 2002;123(5):1702-1704. (Pubitemid 35231669)
25. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42(1):132-138. (Pubitemid 40038911)
26. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev. 2007;(1):CD005166.
27. Basaranoglu M, et al. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol. 1999;31(2):384. (Pubitemid 29349772)
28. Zein Co, et al. Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study. Am J Gastroenterol. 2005;100(1):48-55. (Pubitemid 41623268)
29. Petit JM, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol. 2001;35(2):279-283. (Pubitemid 32803485)
30. Fabris P, et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol. 1998;28(3):514-517. (Pubitemid 28133558)
31. Vidal J, Ferrer JP, Esmatjes E, et al. Diabetes mellitus in patients with liver cirrhosis. Diabetes Res Clin Pract. 1994;25(1):19-25. (Pubitemid 24288042)
32. Phelps G, Chapman I, Hall P, et al. Prevalence of genetic haemochromatosis in diabetic patients. Lancet. 1989;2(8657):233-234. (Pubitemid 19180608)